Gemina Laboratories Ltd.
GLABF · OTC
7/31/2025 | 4/30/2025 | 1/31/2025 | 10/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $11 | $0 | $0 |
| % Growth | -100% | – | – | – |
| Cost of Goods Sold | $2 | $0 | $0 | $0 |
| Gross Profit | -$2 | $11 | $0 | $0 |
| % Margin | – | 100% | – | – |
| R&D Expenses | $102 | $258 | $288 | $384 |
| G&A Expenses | $0 | $446 | $1,108 | $438 |
| SG&A Expenses | $196 | $446 | $1,108 | $438 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $298 | $704 | $1,396 | $822 |
| Operating Income | -$300 | -$693 | -$1,396 | -$822 |
| % Margin | – | -6,367.3% | – | – |
| Other Income/Exp. Net | $2 | -$68 | -$25 | -$42 |
| Pre-Tax Income | -$299 | -$761 | -$1,421 | -$864 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$299 | -$761 | -$1,421 | -$864 |
| % Margin | – | -6,994.2% | – | – |
| EPS | -0.004 | -0.01 | -0.019 | -0.012 |
| % Growth | 62.5% | 46.4% | -64.4% | – |
| EPS Diluted | -0.004 | -0.01 | -0.019 | -0.012 |
| Weighted Avg Shares Out | 76,571 | 73,326 | 73,326 | 73,326 |
| Weighted Avg Shares Out Dil | 76,571 | 73,326 | 73,326 | 73,326 |
| Supplemental Information | – | – | – | – |
| Interest Income | $2 | $6 | $0 | $0 |
| Interest Expense | $0 | $40 | $42 | $42 |
| Depreciation & Amortization | $2 | $29 | $30 | $30 |
| EBITDA | -$297 | -$692 | -$1,348 | -$792 |
| % Margin | – | -6,358.2% | – | – |